May 2025 in “The Journal of Rheumatology” In this case report, two patients with polyautoimmunity and difficult-to-treat lupus erythematosus experienced significant symptom improvement after adding anifrolumab to their regimen, suggesting its potential as an effective add-on therapy for refractory cutaneous symptoms in autoimmune conditions characterized by elevated interferon alpha activity.
1 citations
,
May 2025 in “The Journal of Rheumatology” This study reviewed how Anifrolumab, though often used in real-world settings for SLE patients with neurological symptoms, showed varying effectiveness and required cautious monitoring for adverse effects like thrombocytopenia and cerebrovascular events.
March 2024 in “Poster presentations” This study found that patients with systemic lupus erythematosus reported improvements in symptoms such as fatigue and joint pain after Anifrolumab treatment, with a corresponding decrease in corticosteroid use, although some disease impacts on daily life remained.
This study explored the experiences of systemic lupus erythematosus patients receiving Anifrolumab, revealing improvements in self-reported symptoms and daily life impacts alongside decreased disease activity and lowered corticosteroid use.
1 citations
,
May 2025 in “The Journal of Rheumatology” In this case report, treatment with anifrolumab led to significant improvement in symptoms for a 52-year-old woman with refractory systemic lupus erythematosus, including resolution of chronic lupus headaches resistant to previous therapies.